Carfilzomib for Liver Cancer

This trial explores a drug called Carfilzomib, a type of chemotherapy, to determine its effectiveness in treating liver cancer that has spread from the colon, adrenal glands, or bile ducts. The trial focuses on the safety of delivering this drug directly to the liver using a special pump. Individuals with a hepatic artery infusion pump installed, whose cancer persists after treatment, may be suitable candidates. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative approach.

The trial does not specify if you need to stop taking your current medications. However, you cannot have received any anticancer therapy within 2 weeks before starting the study treatment.

Research has shown that carfilzomib is generally well-tolerated in cancer treatments. Earlier studies reported that most side effects were mild to moderate, such as slight increases in liver enzymes, a common occurrence with many medications. These side effects are usually not serious and can often be managed with regular check-ups.

Carfilzomib is already approved for treating another type of cancer, indicating thorough study. It is not processed by the liver, which might reduce the risk of liver-related side effects. However, a warning exists about possible liver issues, so doctors will closely monitor liver function during treatment.

Carfilzomib is unique because it is delivered directly to the liver through a Hepatic Artery Infusion Pump (HAIP), which allows for continuous administration right to the tumor site. This targeted delivery method is different from the standard systemic chemotherapies for liver cancer, which often affect the whole body and can cause significant side effects. Researchers are excited because carfilzomib is a proteasome inhibitor, which means it works by blocking the protein complexes that cancer cells need to survive, potentially leading to more effective and focused treatment with fewer side effects.

Studies have shown that carfilzomib is a promising drug with positive results in treating certain cancers. It blocks cancer cell growth by targeting parts of the cell that function as recycling centers. In other cancer types, carfilzomib has demonstrated a high success rate and has even improved survival chances in some cases. Lab tests indicate that carfilzomib has moderate effects against liver cancer cells but can significantly enhance other treatments. In this trial, participants with liver metastatic disease will receive continuous administration of carfilzomib via Hepatic Artery Infusion Pump (HAIP) to evaluate its effectiveness specifically for liver cancer.¹²⁶⁷⁸